Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: j g cordes who wrote (25291)	2/23/2000 11:21:00 AM
From: Johnny Canuck	Respond to of 68987

Anyone doing anything with the Super Conductor or Gene Therapy Biotech group? I was asked about both but I don't know the group. It looks like I need to catch up on the super conductors though. ********************************* 10:23 ET Regeneron Pharmaceuticals (REGN) 31 13/16 +10 15/16 (+52%): Merrill Lynch initiates coverage with NT ACCUMULATE and LT BUY ratings based on robust and innovative new product pipeline. 10:05 ET Conductus (CDTS) 39 11/16 +10 3/4 (+37%): --Update-- Issue rallies to new 52-week high; American Superconductor (AMSC 55 +5 1/2) climbs in sympathy. 10:02 ET SoundView On Semis : Semiconductor equipment book-to-bill rose to 1.34 in January, the third highest level in the history of the SEMI Express report... SoundView believes we are still in the early stages of the cycle; projects capital spending increases of 34% in 2000 and 27% in 2001; believes estimates could prove to be conservative. 09:46 ET Conductus (CDTS) 34 7/8 +5 15/16 (+20.5%): Manufacturer of superconducting wireless systems announced that the first field trial of its ClearSite system at a CDMA cell site demonstrated dramatic improvement in base station performance.